ZUG, Switzerland — November 5, 2025 — Leads & Copy — MoonLake Immunotherapeutics (Nasdaq: MLTX) has announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at $10.50 per share. The offering is expected to generate gross proceeds of approximately $75 million for MoonLake, before deducting underwriting discounts, commissions, and other expenses. The offering is expected to close around November 6, 2025, pending customary closing conditions.
The clinical-stage biotechnology company plans to use the net proceeds along with existing resources to fund research and development of sonelokimab and for general corporate purposes.
Leerink Partners is acting as the sole bookrunning manager for the offering. A shelf registration statement related to the securities is on file with the SEC.
Contacts:
MoonLake Immunotherapeutics Media & Investors Relations
ir@moonlaketx.com
ICR Healthcare
Mary-Jane Elliott, Namrata Taak, Ashley Tapp
Tel: +44 (0) 20 3709 5700
MoonLake@ICRHealthcare.com
Source: MoonLake Immunotherapeutics
